

---

## Medical Policy



Nonprofit corporations and independent licensees  
of the Blue Cross and Blue Shield Association

**Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. When Centers for Medicare and Medicaid (CMS) coverage rules are not fully developed, this medical policy may be used by BCBSM or BCN Medicare Advantage plans 42 CFR § 422.101 (b)(6). Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.**

---

**\*Current Policy Effective Date: 7/1/25**  
(See policy history boxes for previous effective dates)

### **Title: Corneal Hysteresis Measurement for Glaucoma**

---

#### **Description/Background**

Corneal hysteresis is an assessment of the cornea's ability to absorb and dissipate energy. The cornea's viscoelasticity measurement is the difference (measured in mm Hg) between the pressure at which the cornea bends inward during an air jet applanation (the abnormal flattening of a convex surface) and the pressure at which it returns to normal. The difference in intraocular pressure recorded during inward and outward flattening (applanation) is corneal hysteresis. The measurement is made during rapid motion of the cornea in response to the short duration (20-ms) air impulse. The air impulse causes the cornea to move inward, through applanation of the convex surface of the eye and into slight concavity. Milliseconds after applanation, the air pump shuts off and the cornea moves through a second applanation, while returning from concavity to its normal convex curvature. The rapid motion of the cornea during deformation creates velocity (rate)-dependent forces that oppose the pressure force created by the air impulse. These opposing forces absorb energy from the air impulse, causing time delays (hysteresis) in the occurrence of the applanation events. The differences in the pressures reflect the viscoelastic biomechanical property of the cornea.

Glaucoma is one of the leading causes of irreversible blindness in the United States. Although certain populations are at a higher risk of developing glaucoma, everyone is at risk for glaucoma and there may be virtually no warning. According to the Centers for Disease Control and Prevention (2022), "more than 3 million Americans have glaucoma" and that number is expected to rise to 6.3 million by 2050. Only 50% of people who have glaucoma are aware of it. Glaucoma is a group of diseases that damage the eye's optic nerve and can result in vision loss and blindness. Although there is no cure, if the disease is found early, it can be treated and managed before vision loss or blindness occurs. Untreated glaucoma will gradually cause

damage to the eye(s), impairing vision in such a way that goes unnoticed until it is in an advanced stage.

Currently, intraocular pressure (IOP) is the most significant risk factor for glaucoma and is the only parameter for which treatment has been demonstrated to decrease glaucoma incidence and progression. IOP is the only modifiable risk factor for the development and progression of glaucoma.

The Goldman applanation tonometer (GAT) is currently, the most widely used method of measuring fluid inside the eye (intraocular pressure). GAT is considered the gold standard for evaluating IOP, which can lead to glaucoma. The tonometer makes a static measurement of the intraocular pressure (IOP) by the force required to flatten a fixed area of the cornea. The IOP measurement is the average derived from 2 pressures (Pressure 1 – inward applanation and Pressure 2 – the pressure at which the cornea returns to normal configuration). The accuracy of GAT depends on many factors, including corneal thickness, corneal curvature, corneal structure and axial length.

---

### **Regulatory Status:**

The Ocular Response Analyzer® (Reichert, Inc) was approved by the United States Food and Drug Administration (2004) through the premarket approval process. The FDA approved label indicates that the ORA device is intended to measure intraocular pressure of the eye and the biomechanical response of the cornea, for the purpose of aiding in the diagnosis and monitoring of glaucoma. An FDA approved update (2008) was received allowing for measurement of intraocular pressure of the eye and biomechanical response of the cornea. Product code: HKX

---

### **Medical Policy Statement**

Corneal hysteresis testing is considered experimental/investigational. It has not been scientifically demonstrated to be as effective as standard testing.

---

### **Inclusionary and Exclusionary Guidelines**

N/A

---

**CPT/HCPCS Level II Codes** *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure)*

### **Established codes:**

N/A

## **Other codes (investigational, not medically necessary, etc.):**

92145

---

### **Rationale**

Martinez-de-la-Casa et al (2004) is an industry sponsored trial which compared intraocular pressure (IOP) measurements obtained with ocular response analyzer (ORA) and the Goldmann applanation tonometer (GAT). ORA readings were consistently higher than GAT measurements (Goldmann-correlated IOP – IOP GAT mean difference,  $7.2 \pm 3.5$  mm Hg; corneal-compensated IOP – IOP GAT mean difference,  $8.3 \pm 4.0$  mm Hg) However, differences were not constant and increased with increasing IOP GAT readings, both with respect to Goldmann-correlated IOP (slope = 0.623,  $P < 0.0001$ ) and corneal-compensated IOP (slope = 0.538,  $P < 0.0001$ ). Both pressure measurements provided by the ORA showed significant correlation with CCT (CCT versus Goldmann-correlated IOP:  $r = 0.460$ ,  $P = 0.001$ ; CCT versus corneal-compensated IOP:  $r = 0.442$ ,  $P = 0.001$ ). No significant effects of corneal curvature or refraction on any of the pressures were observed. Authors concluded that ORA significantly overestimates IOP compared with the GAT. Differences between both sets of measures increase as the GAT-determined IOP increases. ORA readings seem to be affected by central corneal thickness.

Mansouri et al (2011) analyzed the association between corneal biomechanical parameters using the Ocular Response Analyzer (ORA) and glaucoma severity in an observational cross sectional study. Two hundred ninety-nine eyes of 191 patients with confirmed or suspected glaucoma were evaluated. The authors opined that the findings “suggested a weak overall association between corneal biomechanics and disease severity.”

Hayes (2018) identified 16 studies that evaluated CH testing for diagnosis of glaucoma, or for predicting the progression or response to treatment of glaucoma. Eleven prospective or retrospective cohort studies and 5 prospective case-control studies were examined, involving from 52 to 443 patients with follow-up times ranging from 0 to 6.6 years. The report concluded that the test has some capacity to diagnose glaucoma, to predict risk for glaucoma progression, and to predict response of glaucoma to certain types of treatment; however, the evidence is comprised of very poor quality and lacked the rigor to determine diagnostic or prognostic accuracy. The role of CH testing in the management of individuals with glaucoma and its impact on long-term health outcomes could not be determined due to the lack of evidence on the clinical utility of this test. Additional studies are needed to determine whether corneal hysteresis provides accurate diagnosis of glaucoma, prognosis of glaucoma progression, and prognosis of response to treatment. Studies that address these prognostic uses of corneal hysteresis could help establish this technique as a reliable source of information for guidance of glaucoma management.

Sit et al (2022) discussed a TEC assessment performed on behalf of the American Academy of Ophthalmology (AAO). Nineteen articles were reviewed in full text and each assigned a level of evidence rating based on a rating scale developed by the Oxford Centre for Evidence-Based Medicine. Corneal hysteresis was found to be lower in individuals with glaucoma when compared to healthy individuals. Authors concluded that measurement of CH appeared to provide additional information which may be useful during the clinical assessment of individuals who are suspected of having glaucoma; however, interpretation of CH

measurements in an individual was noted to be complicated by the effects of intraocular pressure, as well as medical, laser and surgical therapy and other influencing parameters. The specific tissue properties that contribute to CH remain elusive. Therefore it is unclear if CH is a factor of glaucoma or if CH is a response to elevated IOP or an incidental finding in glaucomatous eyes. Further research is necessary.

Gedde et al (2020) reported that the AAO Preferred Practice Pattern for Primary Open Angle Glaucoma risk factors for glaucoma progression include decreased corneal hysteresis. The association between risk factors such as low corneal hysteresis and the development of glaucomatous optic nerve damage has not been consistently demonstrated.

Maruyama et al (2024) examined the measurement reliability when the Ocular Response Analyzer (ORA) is used as a screening tonometer, and to compare CH measurements in eyes with and those without glaucomatous changes in the fundus. A total of 1488 eyes from 747 subjects (mean age:  $53.5 \pm 20.4$  y, range: 6-94 y) underwent intraocular pressure (IOP) measurement using ORA as screening. Mean  $\pm$  SD (range) of ORA measurements were: Goldmann-correlated IOP  $14.9 \pm 4.8$  (1.0-63.2) mm Hg, corneal-compensated IOP  $16.2 \pm 4.7$  (3.2-73.6) mm Hg, CH  $9.7 \pm 1.5$  (0.0-20.6) mm Hg, and waveform score  $7.3 \pm 1.5$  (0.1-9.7). Eighty-four percent of eyes had a waveform score  $\geq 6$ . Among 192 eyes (127 patients, aged  $53.5 \pm 18.0$  y) with waveform score  $\geq 6$  and evaluable for glaucomatous changes in the fundus. Fifty-three eyes were determined as positive and 139 eyes as negative. CH was  $9.6 \pm 1.4$  (6.8-13.3) mm Hg in the positive group and  $10.2 \pm 1.2$  (6.9-13.3) mm Hg in the negative group and was significantly lower in the positive group (  $P = 0.003$ ). Using ORA as a screening tonometer resulted in reliable findings being obtained in  $\sim 80\%$  of the eyes. CH was lower in the glaucomatous change-positive group compared with the glaucomatous change-negative group.

## Summary

Multiple industry sponsored studies are promoting the use of corneal hysteresis when screening or treating individuals with a high risk of glaucoma development or progression. Existing non-biased literature indicates there is a weak overall association between corneal biomechanics and disease severity as the evidence was found to be of very poor quality. There is insufficient evidence in the peer-reviewed medical literature to establish the role of corneal hysteresis measurement in glaucoma risk assessment.

## PRACTICE GUIDELINES AND POSITION STATEMENTS

At the present time, there are no practice guidelines or position statements that support the use of corneal hysteresis in the assessment and management of glaucoma risk or disease progression.

---

## Government Regulations

### National:

There is no Medicare National Coverage Determination (NCD) for corneal hysteresis. There is a fee listed for procedure code 92145.

### Local:

**Corneal Hysteresis (L38211)** For services performed on or after: 10/14/19 **Revision Date:** 7/27/23

## Coverage Indications, Limitations, and/or Medical Necessity

This is a NON-coverage policy for all **CORNEAL HYSTERESIS** assessments as a means of risk assessment or monitoring for progression of ophthalmic disease activity.

*(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)*

---

## Related Policies

Continuous Intraocular Pressure Monitoring  
Ophthalmologic Techniques for Evaluating Glaucoma  
Optical Coherence Tomography Imaging, Anterior Eye

---

## References

1. Centers for Disease Control and Prevention. "Current Glaucoma Programs." 2022. [https://www.cdc.gov/vision-health/php/glaucoma-programs/?CDC\\_AAref\\_Val=https://www.cdc.gov/visionhealth/research/projects/ongoing/glaucoma.htm](https://www.cdc.gov/vision-health/php/glaucoma-programs/?CDC_AAref_Val=https://www.cdc.gov/visionhealth/research/projects/ongoing/glaucoma.htm). Accessed February 6, 2025.
2. Gedde SJ, Vinod K, Wright MM, et al., American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel. Primary open-angle glaucoma preferred practice pattern®. *Ophthalmology*. 2020 Jan;128(1):P71-P150.
3. Glaucoma Research Foundation, "Glaucoma Facts and Stats," <http://www.glaucoma.org/glaucoma/glaucoma-facts-and-stats.php>. Accessed February 6, 2025.
4. Hayes Health Technology Assessment. "Measurement of corneal hysteresis for the diagnosis and management of glaucoma." 2018 Dec.
5. Kamalipour A, Moghimi S, Eslani M, et al. A prospective longitudinal study to investigate corneal hysteresis as a risk factor of central visual field progression in glaucoma. *Am J Ophthalmol*. 2022 Aug;240:159-169.
6. Martinez-de-la-Casa, J.M., Garcia-Feijoo, J., et al. Ocular Response Analyzer versus Goldmann Applanation Tonometry for Intraocular Pressure Measurements. *Invest. Ophthalmol. Vis. Sci*. 2006;47(10):4410-4414.
7. Maruyama K, Sugiura N, Taki T. :Reliability of Measurements Using Ocular Response Analyzer as a Screening Tonometer and Corneal Hysteresis Values in the Presence or Absence of Glaucomatous Changes in Fundus." *J Glaucoma*. 2024 Mar 1;33(3):183-188. doi: 10.1097/IJG.0000000000002312. Epub 2023 Sep 12. PMID: 37748090.
8. Sit AJ, Chen TC, Takusagawa HL, et al. Corneal hysteresis for the diagnosis of glaucoma and assessment of progression risk: A report by the American Academy of Ophthalmology. *Ophthalmology*. 2023. 130(4):433-442.
9. United States Food and Drug Administration, 510(k) Premarket Notification, K032799, Ocular Response Analyzer, Reichert, Inc. January 20, 2004
10. United States Food and Drug Administration, 510(k) Premarket Notification, K081756, Ocular Response Analyzer, Reichert, Inc. August 7, 2008.

11. Wisconsin Physicians Service (WPS), "Corneal Hysteresis," Local Coverage Determination (L38211), original effective date 10/14/19; <https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=Corneal+Hysteresis&keywordType=starts&areald=s27&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all>. Accessed: February 6, 2025.

*The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through 2/6/25, the date the research was completed.*

### Joint BCBSM/BCN Medical Policy History

<b>Policy Effective Date</b>	<b>BCBSM Signature Date</b>	<b>BCN Signature Date</b>	<b>Comments</b>
9/1/07	8/17/07	8/29/07	Joint policy established
9/1/08	7/3/08	7/3/08	Routine maintenance
9/1/10	6/19/10	6/22/10	Routine maintenance
5/1/12	2/21/12	2/21/12	Routine maintenance
11/1/13	8/22/13	8/27/13	Routine maintenance
3/1/14	12/12/14	12/29/14	Routine maintenance; title changed from "Corneal Hysteresis Determination by Air Impulse Stimulation" to Corneal Hysteresis Measurement for Glaucoma;" code 0181T deleted; new code 92145 added.
7/1/16	4/19/16	4/19/16	Routine maintenance
7/1/17	4/18/17	4/18/17	Routine maintenance LCD added
7/1/18	4/17/18	4/17/18	Routine maintenance
7/1/19	4/16/19		Routine maintenance
7/1/20	4/14/20		Routine maintenance
7/1/21	4/20/21		Routine maintenance
7/1/22	4/19/22		Routine maintenance
7/1/23	4/18/23		Routine maintenance (slp) Vendor Managed: N/A
7/1/24	4/16/24		Routine maintenance (slp) Vendor Managed: N/A
7/1/25	4/15/25		Routine maintenance (slp) Vendor Managed: N/A

Next Review Date: 2<sup>nd</sup> Qtr, 2026

**BLUE CARE NETWORK BENEFIT COVERAGE**  
**POLICY: CORNEAL HYSTERESIS MEASUREMENT FOR GLAUCOMA**

**I. Coverage Determination:**

<b>Commercial HMO (includes Self-Funded groups unless otherwise specified)</b>	Not covered
<b>BCNA (Medicare Advantage)</b>	Refer to Medicare information under the Government Regulations section of this policy.
<b>BCN65 (Medicare Complementary)</b>	Coinsurance covered if primary Medicare covers the service.

**II. Administrative Guidelines:**

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.